Preferential Tumor Targeting of HER2 by iPSC-Derived CAR T Cells Engineered to Overcome Multiple Barriers to Solid Tumor Efficacy

Investigators described an iPSC-derived CAR T cell that combines a human epidermal growth factor receptor 2 (HER2)-targeting CAR with multiplex editing designed to address and overcome obstacles to maximize efficacy in solid tumor indications.